Idiopathic Hyperphosphatasia

ABSTRACT

Idiopathic hyperphosphatasia is a rare autosomal recessive bone disorder, characterized by excessive bone resorption and bone formation. The radiographic appearances include widening of the diaphyses, vertebral osteoporosis, acetabular protrusion, and thickening of the skull vault. There is considerable variability in phenotype, with some cases diagnosed in infancy and others in later childhood. Most cases appear to arise from inactivating mutations in the gene encoding osteoprotegerin, a product of osteoblasts that is critically involved in osteoclastogenesis. Treatment with inhibitors of bone resorption (calcitonin or bisphosphonates) is successful in ameliorating some aspects of the disorder.

KEYWORD

Hyperphosphatasia - juvenile Paget's disease - osteoprotegerin - hyperostosis

REFERENCES

• 1 Bakwin H, Eiger M S. Fragile bones and macrocranium.  J Pediatr . 1956;  49 558-564
• 2 http://www3.ncbi.nlm.nih.gov.htbin-post/Omim/ . 
• 3 Whyte M P, Obrecht S E, Finnegan P M. Osteoprotegerin deficiency and juvenile Paget's disease.  N Engl J Med . 2002;  247 175-184
• 4 Cundy T, Hegde M, Naot D. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype.  Hum Mol Genet . 2002;  11 2119-2127
• 5 Mitsudo S M. Chronic idiopathic hyperphosphatasia associated with pseudoxanthoma elasticum.  J Bone Joint Surg Am . 1971;  83 303-314
• 6 Sharif K W, Doig W M, Kinsella F P. Visual impairment in a case of juvenile Paget's disease with pseudoxanthoma elasticum.  J Pediatr Ophthalmol Strabismus . 1989;  26 299-302
• 7 Simonet W S, Lacey D, Dunstan C R. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.  Cell . 1997;  89 309-319
• 8 Yasuda H, Shima N, Nakagawa N. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.  Endocrinology . 1998;  39 1239-1337
• 9 Mizuno A, Amizuka N, Irie K. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.  Biochem Biophys Res Commun . 1998;  247 610-615
• 10 Bucay N, Saropsi I, Dunstan C R. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.  Genes Dev . 1998;  12 1260-1268
• 11 Pazzaglia U E, Barbieri D, Beluffi G. Chronic idiopathic hyperphosphatasia and fibrous dysplasia in the same child.  J Pediatr Orthop . 1989;  9 709-716
• 12 Dohler J R, Souter W A. Idiopathic hyperphosphatasia with dermal pigmentation.  J Bone Joint Surg Br . 1986;  68 305-310
• 13 Antoniades K, Karakasis G, Lasaridis N, Tzarou V. Chronic idiopathic hyperphosphatasemia.  Oral Surg Oral Med Oral Pathol . 1993;  76 200-204
• 14 Hughes A E, Ralston S H, Marken J. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.  Nat Genet . 2000;  24 45-48
• 15 Whyte M P, Hughes A E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis.  J Bone Miner Res . 2002;  17 26-29
• 16 Blanco O, Stivel M, Mautalen C, Schajowicz F. Familial idiopathic hyperphosphatasia.  J Bone Joint Surg Br . 1977;  59 421-427
• 17 Cassinelli H R, Mautelen C A, Heinrich J J, Miglietta A, Bergada C. Familial idiopathic hyperphosphatasia: response to long-term treatment with pamidronate.  Bone Miner . 1992;  19 175-184
• 18 Tuysuz B, Mercimek S, Unger S, Deniz M. Calcitonin treatment in osteoectasia with hyperphosphatasia (juvenile Paget's disease).  Pediatr Radiol . 1999;  29 838-841
• 19 Doyle F H, Woodhouse N JY, Glen A CA, Joplin G F, MacIntyre I. Healing of the bones in juvenile Paget's disease treated by human calcitonin.  Br J Radiol . 1974;  47 9-15
• 20 Min H S, Morony S, Sarosi I. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.  J Exp Med . 2000;  192 463-474